ReviewHealth science reports2025
Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti-HER2 Therapy) and Radiotherapy: Systematic Review and Meta-Analysis.
Review in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.Frontiers in oncology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Concomitant administration of trastuzumab (Tra) and radiotherapy (RT) has been known as an effective strategy for treating HER2-positive breast cancer (HER2 Methods: A systematic review was conducted on the databases of PubMed, WOS, and Scopus up to 2024. The decline in left ventricular ejection fraction (LVEF) from baseline was assessed as a cardiac toxicity indicator, LVEF reduction Grade 1 (LVEF 60%-50%), Grade 2 (LVEF 50%-40%), and Grade 3 (LVEF 40%-20%). Results: Seven studies meeting defined criteria were included in this investigation. This study examined the prevalence of LVEF-grade 1-3 in HER2 Conclusion: Cardiotoxic effects of chemotherapy and RT may accumulate and lead to heart failure so early diagnosis methods are advised. Concurrent RT with Tra is well-tolerated clinically, and coadministration does not significantly raise primary cardiotoxicity. Cardiac toxicity may occur in some patients, requiring long-term follow-up to assess the impact of combining Tra and RT on heart function and its correlation with patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.